BridgeBio Pharma Inc. published a document on the CLARIFY disease monitoring study, which is a global, multicenter, longitudinal, non-interventional study. The study aims to understand the disease burden, management, and progression in pediatric and adult participants with Autosomal Dominant Hypocalcemia Types 1 and 2 (ADH1/2) over five years. The document includes details on the study design, methods, and baseline characteristics of pediatric participants. The full document can be accessed through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。